{"id":401504,"date":"2020-12-17T01:03:16","date_gmt":"2020-12-17T06:03:16","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=401504"},"modified":"2020-12-17T01:03:16","modified_gmt":"2020-12-17T06:03:16","slug":"sequana-medical-announces-january-2021-investor-conference-schedule","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sequana-medical-announces-january-2021-investor-conference-schedule\/","title":{"rendered":"Sequana Medical Announces January 2021 Investor Conference Schedule"},"content":{"rendered":"
\n

GHENT, Belgium, Dec. 17, 2020 (GLOBE NEWSWIRE) — Sequana Medical NV (Euronext Brussels: SEQUA)<\/strong>, an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces that its management team will participate in two upcoming virtual investor conferences, being held in parallel with the JP Morgan 39th Annual Healthcare Conference.<\/p>\n

\n
\n 10<\/strong>
\n <\/a>
\n
\n
\n th<\/strong>
\n <\/sup>
\n <\/a>
\n
\n Annual LifeSci Advisors Corporate Access Event<\/strong>
\n <\/a>
\n , <\/strong>
\n 6-8 and 11-14 January 2021<\/strong>\n <\/p>\n

\n
\n H.C. Wainwright Bioconnect<\/strong>
\n <\/a>
\n
\n 2021<\/strong>
\n <\/a>
\n , <\/strong>
\n 11-14 January 2021<\/strong>
\n
The company presentation with webcast by Ian Crosbie, CEO, will be available on demand as of 11 January 2021 on the Conference website and on the Sequana Medical Investors website<\/a>.<\/p>\n

To request a one-on-one meeting with Sequana Medical management at one of these events, contact us at IR@sequanamedical.com.<\/p>\n

\n For more information, please contact: <\/strong>\n <\/p>\n

\n Sequana Medical<\/strong>
\n
Lies Vanneste, Director Investor Relations
Tel: +32 498 05 35 79
Email: IR@sequanamedical.com<\/a><\/p>\n\n\n
\n Consilium Strategic Communications <\/strong>
\n
Amber Fennell, Ashley Tapp, Melissa Gardiner
Tel: +44 203 709 5000
Email: sequanamedical@consilium-comms.com<\/a>\u00a0\u00a0<\/td>\n		\n LifeSci Advisors<\/strong>
\n
Chris Maggos
Tel: +41 79 367 6254
Email: chris@lifesciadvisors.com<\/a>\u00a0\u00a0\u00a0 <\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\n About Sequana Medical<\/strong>
\n
Sequana Medical is a commercial stage medical device company developing the alfa<\/strong>pump platform for the management of fluid overload in liver disease, malignant ascites and heart failure where diuretics are no longer effective. Fluid overload is a fast growing complication of advanced liver disease driven by NASH (non-alcoholic steatohepatitis) related cirrhosis and a common complication in heart failure. The U.S. market for the alfa<\/strong>pump resulting from NASH-related cirrhosis is forecast to exceed \u20ac3 billion annually within the next 10-20 years. The heart failure market for the alfa<\/strong>pump DSR (Direct Sodium Removal) is estimated to be over \u20ac5 billion annually in the U.S. and EU5 by 2026. Both indications leverage Sequana Medical’s alfa<\/strong>pump, a unique, fully implanted wireless device that automatically pumps fluid from the abdomen into the bladder, where it is naturally eliminated through urination.<\/p>\n

In the U.S., the company’s key growth market, the alfa<\/strong>pump has been granted breakthrough device designation by the FDA for recurrent or refractory ascites due to liver cirrhosis. Interim data from the ongoing North American pivotal study (POSEIDON) showed positive outcomes against all primary endpoints of the study. This study is intended to support a future marketing application of the alfa<\/strong>pump in the U.S. and Canada. In Europe, the alfa<\/strong>pump is CE-marked for the management of refractory ascites due to liver cirrhosis and malignant ascites and is included in key clinical practice guidelines. Over 800 alfa<\/strong>pump systems have been implanted to date. Building on its proven alfa<\/strong>pump platform, Sequana Medical is developing the alfa<\/strong>pump DSR, a breakthrough, proprietary approach to fluid overload due to heart failure. Clinical proof-of-concept was achieved in a first-in-human single dose DSR study and further supported by strong interim safety and efficacy results from the ongoing repeated dose alfa<\/strong>pump DSR study (RED DESERT) in heart failure patients.<\/p>\n

Sequana Medical is headquartered in Ghent, Belgium. For further information, please visit www.sequanamedical.com<\/a>.<\/p>\n

\n
\n Important Regulatory Disclaimers<\/em>
\n <\/strong>
\n
\n The\u00a0<\/em>
\n
\n alfa<\/em>
\n <\/strong>
\n pump\u00ae<\/sup> system is not currently approved in the United States or Canada. In the United States and Canada, the\u00a0<\/em>
\n
\n alfa<\/em>
\n <\/strong>
\n pump\u00ae<\/sup> system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. For more information regarding the POSEIDON clinical study see\u00a0<\/em>
\n
\n www.poseidonstudy.com<\/em>
\n <\/a>
\n . The DSR therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. The DSR therapy is not currently approved for clinical research in the United States or Canada. There is no link between the DSR therapy and ongoing investigations with the\u00a0<\/em>
\n
\n alfa<\/em>
\n <\/strong>
\n pump\u00ae<\/sup> system in Europe, the United States or Canada.<\/em>\n <\/p>\n

\n
\n Forward-looking statements<\/em>
\n <\/strong>
\n
\n This press release may contain predictions, estimates or other information that might be considered forward-looking statements. Such forward-looking statements are not guarantees of future performance. These forward-looking statements represent the current judgment of Sequana Medical on what the future holds, and are subject to risks and uncertainties that could cause actual results to differ materially. Sequana Medical expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release, except if specifically required to do so by law or regulation. You should not place undue reliance on forward-looking statements, which reflect the opinions of Sequana Medical only as of the date of this press release.<\/em>\n <\/p>\n

\u00a0<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

GHENT, Belgium, Dec. 17, 2020 (GLOBE NEWSWIRE) — Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces that its management team will participate in two upcoming virtual investor conferences, being held in parallel with the JP Morgan 39th Annual Healthcare Conference. 10 th Annual LifeSci Advisors Corporate Access Event , 6-8 and 11-14 January 2021 H.C. Wainwright Bioconnect 2021 , 11-14 January 2021 The company presentation with webcast by Ian Crosbie, CEO, will be available on demand as of 11 January 2021 on the Conference website and on the Sequana Medical Investors website. To request a one-on-one meeting with Sequana Medical management at one of … <\/p>\n

Continue reading “Sequana Medical Announces January 2021 Investor Conference Schedule”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-401504","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSequana Medical Announces January 2021 Investor Conference Schedule - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sequana-medical-announces-january-2021-investor-conference-schedule\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sequana Medical Announces January 2021 Investor Conference Schedule - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"GHENT, Belgium, Dec. 17, 2020 (GLOBE NEWSWIRE) — Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces that its management team will participate in two upcoming virtual investor conferences, being held in parallel with the JP Morgan 39th Annual Healthcare Conference. 10 th Annual LifeSci Advisors Corporate Access Event , 6-8 and 11-14 January 2021 H.C. Wainwright Bioconnect 2021 , 11-14 January 2021 The company presentation with webcast by Ian Crosbie, CEO, will be available on demand as of 11 January 2021 on the Conference website and on the Sequana Medical Investors website. To request a one-on-one meeting with Sequana Medical management at one of … Continue reading "Sequana Medical Announces January 2021 Investor Conference Schedule"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sequana-medical-announces-january-2021-investor-conference-schedule\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-17T06:03:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzQ2OSMzODg0OTYyIzUwMDA2NjM3Mw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sequana-medical-announces-january-2021-investor-conference-schedule\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sequana-medical-announces-january-2021-investor-conference-schedule\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Sequana Medical Announces January 2021 Investor Conference Schedule\",\"datePublished\":\"2020-12-17T06:03:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sequana-medical-announces-january-2021-investor-conference-schedule\\\/\"},\"wordCount\":724,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sequana-medical-announces-january-2021-investor-conference-schedule\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMzQ2OSMzODg0OTYyIzUwMDA2NjM3Mw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sequana-medical-announces-january-2021-investor-conference-schedule\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sequana-medical-announces-january-2021-investor-conference-schedule\\\/\",\"name\":\"Sequana Medical Announces January 2021 Investor Conference Schedule - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sequana-medical-announces-january-2021-investor-conference-schedule\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sequana-medical-announces-january-2021-investor-conference-schedule\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMzQ2OSMzODg0OTYyIzUwMDA2NjM3Mw==\",\"datePublished\":\"2020-12-17T06:03:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sequana-medical-announces-january-2021-investor-conference-schedule\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sequana-medical-announces-january-2021-investor-conference-schedule\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sequana-medical-announces-january-2021-investor-conference-schedule\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMzQ2OSMzODg0OTYyIzUwMDA2NjM3Mw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMzQ2OSMzODg0OTYyIzUwMDA2NjM3Mw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sequana-medical-announces-january-2021-investor-conference-schedule\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sequana Medical Announces January 2021 Investor Conference Schedule\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sequana Medical Announces January 2021 Investor Conference Schedule - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sequana-medical-announces-january-2021-investor-conference-schedule\/","og_locale":"en_US","og_type":"article","og_title":"Sequana Medical Announces January 2021 Investor Conference Schedule - Market Newsdesk","og_description":"GHENT, Belgium, Dec. 17, 2020 (GLOBE NEWSWIRE) — Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces that its management team will participate in two upcoming virtual investor conferences, being held in parallel with the JP Morgan 39th Annual Healthcare Conference. 10 th Annual LifeSci Advisors Corporate Access Event , 6-8 and 11-14 January 2021 H.C. Wainwright Bioconnect 2021 , 11-14 January 2021 The company presentation with webcast by Ian Crosbie, CEO, will be available on demand as of 11 January 2021 on the Conference website and on the Sequana Medical Investors website. To request a one-on-one meeting with Sequana Medical management at one of … Continue reading \"Sequana Medical Announces January 2021 Investor Conference Schedule\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sequana-medical-announces-january-2021-investor-conference-schedule\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-17T06:03:16+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzQ2OSMzODg0OTYyIzUwMDA2NjM3Mw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sequana-medical-announces-january-2021-investor-conference-schedule\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sequana-medical-announces-january-2021-investor-conference-schedule\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Sequana Medical Announces January 2021 Investor Conference Schedule","datePublished":"2020-12-17T06:03:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sequana-medical-announces-january-2021-investor-conference-schedule\/"},"wordCount":724,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sequana-medical-announces-january-2021-investor-conference-schedule\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzQ2OSMzODg0OTYyIzUwMDA2NjM3Mw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sequana-medical-announces-january-2021-investor-conference-schedule\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sequana-medical-announces-january-2021-investor-conference-schedule\/","name":"Sequana Medical Announces January 2021 Investor Conference Schedule - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sequana-medical-announces-january-2021-investor-conference-schedule\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sequana-medical-announces-january-2021-investor-conference-schedule\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzQ2OSMzODg0OTYyIzUwMDA2NjM3Mw==","datePublished":"2020-12-17T06:03:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sequana-medical-announces-january-2021-investor-conference-schedule\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sequana-medical-announces-january-2021-investor-conference-schedule\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sequana-medical-announces-january-2021-investor-conference-schedule\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzQ2OSMzODg0OTYyIzUwMDA2NjM3Mw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzQ2OSMzODg0OTYyIzUwMDA2NjM3Mw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sequana-medical-announces-january-2021-investor-conference-schedule\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Sequana Medical Announces January 2021 Investor Conference Schedule"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/401504","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=401504"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/401504\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=401504"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=401504"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=401504"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}